Quinolone-based first, second and third-line therapies for Helicobacter pylori

Table 1 Studies investigating first-line levofloxacin-based triple therapies

Ref.	Year	Country	PPI	Eradicated/enrolled patients	Duration (d)	ITT rate
Qian et al[30]	2012	China	Esomeprazole	269/345	7	78.1%
Cuadrado-Lavín et al[31]	2012	Spain	Omeprazole	207/250	10	82.8%
Pan et al[32]	2010	China	Esomeprazole/rabeprazole	173/199	7	87.1%
Assem et al[33]	2010	Egypt	Esomeprazole	381/450	7	84.7%
Erçin et al[34]	2010	Turkey	Lansoprazole	66/91	14	72.0%
Liou et al[35]	2010	Taiwan	Lansoprazole	320/432	7	74.0%
Chen et al[36]	2010	China	Esomeprazole	222/300	7	74.0%
Molina-Infante et al[37]	2010	Spain	Omeprazole	380/460	10	82.6%
Castro-Fernández et al[38]	2009	Spain	All PPI	97/135	10	71.8%
Rispo et al[39]	2007	Italy	Esomeprazole	118/130	7	90.8%
Lee et al[40]	2006	South Korea	All PPI	186/267	7	69.8%
Total				2419/3059		79.1%

The dose of levofloxacin was 500 mg b.i.d and amoxicillin 1 g b.i.d for all studies. PPI: Proton pump inhibitor; ITT: Intention to treat.